43 related articles for article (PubMed ID: 38643353)
1. Multiplex imaging reveals spatially resolved DNA-damage response neighborhoods in TP53-mutated myelodysplastic neoplasms.
Yeung T; Zhang Y; Kennedy B; Walsh C; Love T; Xia D; Bhattacharya A; Krishnan RG; Head D; Burack R
J Pathol; 2024 Jul; 263(3):386-395. PubMed ID: 38801208
[TBL] [Abstract][Full Text] [Related]
2. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
[TBL] [Abstract][Full Text] [Related]
4. Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias.
Dunphy CH; O'Malley DP; Perkins SL; Chang CC
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):154-9. PubMed ID: 17525626
[TBL] [Abstract][Full Text] [Related]
5. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
[TBL] [Abstract][Full Text] [Related]
6. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38643353
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
9. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
Siddon AJ; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
[TBL] [Abstract][Full Text] [Related]
11. Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia.
Vonk CM; Al Hinai ASA; Hanekamp D; Valk PJM
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771594
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
